Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

4.165 -0.185 (-4.25%)
Delayed Quote Updated: 1:46 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of First Quarter Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.